menu
    • menu
    [{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Inapplicable","moa":"||MCO","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope Therapeutics \/ National Eye Institute"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"}]

    Find Ophthalmology Clinical Drug Pipeline Developments & Deals by Nanoscope Therapeutics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanoscope Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Nanoscope Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MCO-020,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

                            Details : Nanoscope’s MCO-020 gene therapy program is based on targeted laser-delivery of optogenes to areas of geographic atrophy in advanced AMD patients, and currently undergoing IND-enabling studies.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 09, 2022

                            Lead Product(s) : MCO-020,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanoscope Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Nanoscope Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonpiretigene Isteparvovec,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : National Eye Institute

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Nanoscope Awarded $1.5M Phase 2B SBIR Grant to Advance Ambient Light Activatable Opsin Gene Therapy to Restore...

                            Details : Nanoscope’s lead MCO gene therapy, MCO-010, is in a late-stage Phase 2b trial for retinitis pigmentosa (RP) in the US. MCO-010 has orphan drug designations for RP and Stargardt disease from the US Food and Drug Administration.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : Sonpiretigene Isteparvovec,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : National Eye Institute

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth